EC
IPHA

EcoR1 Capital’s Innate Pharma IPHA Stock Holding History

EcoR1 Capital’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-4,465,668
Closed -$29.8M – 59
2020
Q1 		$29.8M Sell
4,465,668
-79,786
-2% -$538K 3.12% 13
2019
Q4 		$29.3M Buy
+4,545,454
New +$27.9M 2.64% 14

Other funds holding IPHA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

EcoR1 Capital's IPHA Position: Q2 2020 in Review

EcoR1 Capital sold out of Innate Pharma (IPHA) in Q2 2020, closing a stake of 4,465,668 shares — an estimated $29.8M sold.

EcoR1 Capital first reported a position in IPHA in Q4 2019 and held it in 2 quarters. The position peaked at $29.8M in Q1 2020. 7 funds tracked by Wall St. Rank hold IPHA as of Q2 2020.

  • EcoR1 Capital reported no remaining Innate Pharma position as of Q2 2020 after selling out during the quarter.
  • EcoR1 Capital sold 4,465,668 Innate Pharma shares in Q2 2020, an estimated $29.8M.
  • EcoR1 Capital first reported a position in Innate Pharma in Q4 2019 and held it in 2 quarters.
  • EcoR1 Capital's Innate Pharma position peaked at $29.8M in Q1 2020.
  • 7 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2020.

Based on EcoR1 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.